Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.

JAMA oncology（2023）

引用 11|浏览29

暂无评分

摘要

ClinicalTrials.gov Identifier: NCT03836066.

查看译文

关键词

non–small cell lung cancer,lung cancer,bevacizumab,high tumor mutation burden,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要